Neos Therapeutics Announces Date Of Second Quarter 2015 Financial Results
Company to Hold First Quarterly Call as a Public Company on September 3, 2015
Dallas-Fort Worth, TX – (August 25, 2015) – Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company with a late-stage pipeline of innovative extended-release (“XR”) product candidates for the treatment of attention deficit hyperactivity disorder (“ADHD”), today announced that it will report financial results for the second quarter and first half of 2015 before the market opens on Thursday, September 3, 2015. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update.
To access the call, dial 866-842-7969 (U.S.) or 704-908-0466 (outside of the U.S.). The Conference ID is 19474416. A live webcast will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Please log in approximately 5-10 minutes prior to the scheduled start time.
The archived webcast will be available on the company’s Investor Relations page under Presentations.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platform. The Company is initially focusing on ADHD and has developed three branded product candidates that are XR medications in patient-friendly orally disintegrating tablets (“ODT”) or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®[1], an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
[1] Tussionex® is a registered trademark of the UCB Group of Companies
CONTACTS:
Richard I. Eisenstadt, Chief Financial Officer Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
David Carey, Investor Relations
Lazar Partners
(212) 867-1768
dcarey@lazarpartners.com
Help employers find you! Check out all the jobs and post your resume.
Dallas-Fort Worth, TX – (August 25, 2015) – Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company with a late-stage pipeline of innovative extended-release (“XR”) product candidates for the treatment of attention deficit hyperactivity disorder (“ADHD”), today announced that it will report financial results for the second quarter and first half of 2015 before the market opens on Thursday, September 3, 2015. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update.
To access the call, dial 866-842-7969 (U.S.) or 704-908-0466 (outside of the U.S.). The Conference ID is 19474416. A live webcast will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Please log in approximately 5-10 minutes prior to the scheduled start time.
The archived webcast will be available on the company’s Investor Relations page under Presentations.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platform. The Company is initially focusing on ADHD and has developed three branded product candidates that are XR medications in patient-friendly orally disintegrating tablets (“ODT”) or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®[1], an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
[1] Tussionex® is a registered trademark of the UCB Group of Companies
CONTACTS:
Richard I. Eisenstadt, Chief Financial Officer Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
David Carey, Investor Relations
Lazar Partners
(212) 867-1768
dcarey@lazarpartners.com
Help employers find you! Check out all the jobs and post your resume.